NASDAQ:ACRX
Delisted
AcelRx Pharmaceuticals Stock News
$0.86
+0 (+0%)
At Close: Apr 08, 2024
SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
05:14pm, Thursday, 01'st Jul 2021
SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACELRX--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Thera
BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G.
New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX
New York, New York--(Newsfile Corp. - June 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) betwe
LOS ANGELES, June 25, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired
New York, New York--(Newsfile Corp. - June 24, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" o
NEW YORK--(BUSINESS WIRE)-- #ACRX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 an
NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class acti
NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17,
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the
AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials
08:30am, Thursday, 17'th Jun 2021
HAYWARD, Calif., June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pu
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
